Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INHALATIONAL DRUG R&D POINTS-TO-CONSIDER PREVIEW

Executive Summary

INHALATIONAL DRUG R&D POINTS-TO-CONSIDER PREVIEW to FDA's Pulmonary-Allergy Advisory Committee July 14 outlines trials the agency suggests would aid in the approval of new metered-dose inhaler products, crossover studies for products making the switch from chlorofluorocarbon-based propellants to other delivery systems and the trials needed for approval of dry powder and pediatric formulations. Still in development, the agency's Points to Consider for Clinical Development of Metered-Dose Inhalers and Dry Powder Inhalers was presented by Pulmonary-Oncology Division Medical Reviewer Babatunde Otulana, MD.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024782

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel